JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 20, 2005; DOI: 10.1124/jpet.105.092080


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.092080v1
316/1/176    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nozawa, M.
Right arrow Articles by Fujimura, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nozawa, M.
Right arrow Articles by Fujimura, A.


Received for publication July 15, 2005.
Revised September 14, 2005.
Accepted for publication September 14, 2005.

Dosing-Time-Dependent Effect of Temocapril on the Mortality of Stroke-Prone Spontaneously Hypertensive Rats

Masahiko Nozawa 1, Koh-ichi Sugimoto 1, Masami Ohmori 1, Hitoshi Ando 1, Akio Fujimura 1*

1 Jichi Medical School

* Address correspondence to: E-mail: akiofuji{at}jichi.ac.jp

Abstract

This study was undertaken to evaluate a dosing-time-dependent effect of temocapril, an angiotensin-converting enzyme (ACE) inhibitor, on the mortality of stroke-prone spontaneously hypertensive rats (SHRSP). Temocapril (1 mg/kg/day) prolonged the survival rate of these animals, with a maximum effect after dosing at the early resting period and a minimum effect after dosing at the early active period. The pharmacokinetics of temocaprilat, an active metabolite of temocapril, did not differ significantly between the two dosing times. However, the inhibition of ACE activity in serum and organs (brain and aorta) and the reduction of blood pressure were significantly greater after dosing at the early resting period than at the early active period. These data suggest that the effect of temocapril on the mortality of SHRSP depends on the time of dosing, with a maximum effect seen after dosing at the early resting period. Dosing-time-dependent differences in the pharmacodynamics of temocapril might be involved in explaining this phenomenon.


Key words: ACE inhibitor, SHR, chronotherapy, hypertension, mortality, temocapril





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.